Product Details

Nat-Ondansetron

Ondansetron Hydrochloride
4 mg
Tablet


DIN/PIN/NPN

02417839

Manufacturer

Natco Pharma (Canada) Inc.

Formulary Listing Date

2015-06-29  

Unit Price

3.3495

Amount MOH Pays

2.5450

Coverage Status

Limited Use Product

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

A04AA01

Interchangeable Products

DIN/ PIN/ NPN Brand name Unit Price Amount MOH pays
02213567 Zofran 15.4760 2.5450
02376091 Septa-Ondansetron 3.3495 2.5450
02274310 Sandoz Ondansetron 3.3495 2.5450
02312247 Ran-Ondansetron 3.3495 2.5450
02258188 PMS-Ondansetron 3.3495 2.5450
02421402 Ondansetron 3.2720 2.5450
02417839 Nat-Ondansetron 3.3495 2.5450
02297868 Mylan-Ondansetron 3.3495 2.5450
02305259 Mint-Ondansetron 3.3495 2.5450
02371731 Mar-Ondansetron 3.3495 2.5450
02313685 Jamp-Ondansetron 3.3495 2.5450
02458810 CCP-Ondansetron 3.3495 2.5450
02288184 Apo-Ondansetron 3.3495 2.5450
02296349 Teva-Ondansetron 3.3495 2.5450
02478927 Accel-Ondansetron 2.5450 2.5450
02541424 Ondansetron 3.3495 2.5450
 

LU Clinical Criteria

LU Code Auth. Period Clinical Criteria
Note: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven
215 1 year

For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy

216 1 year

For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics

217 1 year

For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics

218 1 year

For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation.

454 1 year

For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens

 

EAP Criteria

Therapeutic Class Reimbursement Criteria
Unclassified EAP Drugs

These drugs are not currently listed in the Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs – August 8, 2023 Edition

Physicians may wish to contact the EAP directly by phone at 416-327-8109 or 1-866-811-9893 or by email at EAPFeedback.MOH@ontario.ca to see if an unlisted drug product and/or indication may be considered for EAP funding.

Product Monograph

View Monograph